Gujarat Kidney Q2 FY26 Standalone Profit After Tax Rs 230.12 Lacs
Gujarat Kidney And Super Speciality Limited reported standalone Profit After Tax of ₹230.12 Lacs for Q2 FY26, down from ₹389.98 Lacs in Q2 FY25. Revenue from operations decreased to ₹964.26 Lacs from ₹1,144.99 Lacs year-on-year. Consolidated PAT for H1 FY26 was ₹827.96 Lacs.
The financial results show a decline in key performance indicators like profit and revenue, which can have a moderate impact on investor sentiment and the company's stock price. However, the consolidated results show a profit, mitigating the impact.
The company reported a decrease in Profit After Tax and revenue from operations for the quarter ended September 30, 2025, compared to the same period in the previous year, indicating a negative financial performance trend.
Gujarat Kidney And Super Speciality Limited has announced its unaudited standalone financial results for the second quarter and six months ended September 30, 2025. The company reported a standalone Profit After Tax (PAT) of ₹230.12 Lacs for the quarter ended September 30, 2025, compared to ₹389.98 Lacs in the same period last year. Revenue from operations for the quarter stood at ₹964.26 Lacs, a decrease from ₹1,144.99 Lacs in the corresponding quarter of the previous year. For the six months ended September 30, 2025, the standalone PAT was ₹620.10 Lacs, with revenue from operations at ₹2,109.25 Lacs. The company also provided consolidated financial results, showing a consolidated Profit After Tax of ₹827.96 Lacs for the half-year ended September 30, 2025, with revenue from operations at ₹2,688.81 Lacs. The Board of Directors approved these results on February 14, 2026. The financial statements have been prepared in accordance with Indian Accounting Standard 34 and reviewed by Y. M. Shah & Co., Chartered Accountants, who issued an unmodified limited review report.
What to do with a filing like this
Gujarat Kidney And Super Speciality Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Kidney And Super Speciality Limited. Read the original for the full detail.